Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.88 USD | +3.06% | +22.70% | +81.35% |
Apr. 23 | Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU | MT |
Apr. 22 | RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+81.35% | 1.8B | |
+24.94% | 48.09B | |
+47.24% | 40.62B | |
-2.99% | 40.43B | |
-6.20% | 28.36B | |
+7.40% | 24.89B | |
-19.31% | 19.01B | |
+28.62% | 12.09B | |
-0.87% | 11.88B | |
-0.99% | 11.8B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Wedbush Raises Edgewise Therapeutics' PT to $26 From $23, Continues to See 2024 as Critical Year; Keeps Outperform Rating